TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38428649

Group type: EXPERIMENTAL
Intervention: Higher baseline values of quinolinic acid, PAr, and HKr
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Higher baseline concentrations of neopterin and 3-hydroxykynurenine
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Higher concentrations of xanthurenic acid
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Higher concentrations of neopterin and lower values of pyridoxal 5́-phosphate
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Lower concentrations of picolinic acid
Number of subjects: 422
Study: 38428681

Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy in 5 fractions
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT) at 40 Gy (DL1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy (DL2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT)
Number of subjects: 9
Study: 38428740

Group type: EXPERIMENTAL
Intervention: Weight-loss dietary intervention
Number of subjects: 536
Study: 38428741

Group type: EXPERIMENTAL
Intervention: Total energy intake (EI) biomarker developed from doubly labeled water (DLW) total energy expenditure (TEE) and weight variation during a 2-week DLW protocol period.
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Total energy intake (EI) among participants with stable or increasing weight.
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Total energy intake (EI) among participants with preceding weight loss.
Number of subjects: 1284
Study: 38428970

Group type: EXPERIMENTAL
Intervention: Active αTMS
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study: 38428980

Group type: EXPERIMENTAL
Intervention: TAPSE/sPAP < 0.40 mm/mmHg
Number of subjects: 333
Study: 38429056

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM) accompanied by access to the web-based cardiovascular educational portal (Kvatchii)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home blood pressure monitoring (HBPM) alone
Number of subjects: 200
Study: 38429067

Group type: EXPERIMENTAL
Intervention: Cycloplegic objective wavefront-based refraction
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-cycloplegic objective wavefront-based refraction
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Subjective refraction with cyclopentolate
Number of subjects: 84
Study: 38429079

Group type: EXPERIMENTAL
Intervention: Group-based trajectory models (GBTM) with 4 distinct trajectories
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Baseline FACT-PWB
Number of subjects: 343
Study: 38429085

Group type: EXPERIMENTAL
Intervention: Multi-cancer early detection (MCED) screening programme
Number of subjects: 0
Study: 38429253

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enoxaparin (1 mg/kg twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Edoxaban and Enoxaparin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 40
Study: 38429311

Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients during CRT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients post-CRT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Detectable ctDNA during CRT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Detectable ctDNA post-CRT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High bTMB levels during CRT
Number of subjects: 42
Study: 38429618

Group type: EXPERIMENTAL
Intervention: Behavioral Economic (BE) intervention delivered by a registered nurse and social worker for three months
Number of subjects: 331

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 331
Study: 38429621

Group type: EXPERIMENTAL
Intervention: AChE activity in viral sepsis
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BChE activity in viral sepsis
Number of subjects: 108

Group type: COMPARATOR
Intervention: AChE activity in nonviral sepsis
Number of subjects: 108

Group type: COMPARATOR
Intervention: BChE activity in nonviral sepsis
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 108
Study: 38429839

Group type: EXPERIMENTAL
Intervention: TAU plus Maze Out
Number of subjects: 94

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 94
Study: 38430084

Group type: EXPERIMENTAL
Intervention: ReDS-guided decongestion strategy (discharge criteria requiring an ReDS value of ≤35%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care strategy (discharge criteria based on current clinical practice)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ReDS-guided decongestion strategy
Number of subjects: 100
Study: 38430246

Group type: EXPERIMENTAL
Intervention: Luminal-CD8
Number of subjects: 889

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 889
Study: 38430272

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (0.3 mg/kg intravenous every 12 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 38430288

Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 32
Study: 38430309

Group type: EXPERIMENTAL
Intervention: Lesional skin of LP patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nonlesional skin of LP patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 38430375

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: EXTREME regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Durvalumab monotherapy and durvalumab plus tremelimumab
Number of subjects: 0
Study: 38430402

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 806

Group type: COMPARATOR
Intervention: Antimuscarinics
Number of subjects: 806
Study: 38430405

Group type: EXPERIMENTAL
Intervention: AZD4635 + durvalumab
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: AZD4635 + oleclumab
Number of subjects: 59

Group type: COMPARATOR
Intervention: AZD4635
Number of subjects: 59
Study: 38430413

Group type: EXPERIMENTAL
Intervention: Experimental new technology (NT) stems
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard (STD) stems
Number of subjects: 53
Study: 38430550

Group type: EXPERIMENTAL
Intervention: Osteoporosis group (OP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38431043

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2320
Study: 38431079

Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial volume (LAV) at rest
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial volume (LAV) during exercise-stress
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial area (LAA) at rest
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial area (LAA) during exercise-stress
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LAV PCWP during exercise-stress
Number of subjects: 75

Group type: COMPARATOR
Intervention: LAV PCWP (rest) vs LAV PCWP (stress)
Number of subjects: 75

Group type: COMPARATOR
Intervention: LAA PCWP (rest) vs LAA PCWP (stress)
Number of subjects: 75
Study: 38431102

Group type: EXPERIMENTAL
Intervention: EUS-guided elastography (EUS-EG)
Number of subjects: 53
Study: 38431103

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation system (CBAS)
Number of subjects: 15
Study: 38431130

Group type: EXPERIMENTAL
Intervention: Combined exercise fitness and intensive pelvic floor muscle training program
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study: 38431131

Group type: EXPERIMENTAL
Intervention: 100 mg of hydrocortisone parenterally every 8 hours for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg of hydrocortisone
Number of subjects: 0
Study: 38431133

Group type: EXPERIMENTAL
Intervention: Tailored medication adherence-promotion intervention
Number of subjects: 0
Study: 38431134

Group type: EXPERIMENTAL
Intervention: TAU plus tFOCUS (12-week intervention including a patient-facing mHealth app, clinician-facing web dashboard, and mHealth aftercare advisors)
Number of subjects: 180

Group type: COMPARATOR
Intervention: TAU plus standard discharge planning and aftercare (CHECK-IN)
Number of subjects: 180
Study: 38431156

Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCov-19) two-dose primary series
Number of subjects: 4500000
Study: 38431284

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) participation
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: High optimism levels
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Psychological factors (anxiety, pessimism, resilience)
Number of subjects: 1682
Study: 38431295

Group type: EXPERIMENTAL
Intervention: Standard of care supplemented with a harm reduction kiosk
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard of care (fixed-site, staffed syringe service programme)
Number of subjects: 750
Study: 38431296

Group type: EXPERIMENTAL
Intervention: High societal costs (top 25th percentile) after 1 year of follow-up
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: High costs related to healthcare utilisation after 1 year of follow-up
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: High costs related to productivity loss after 1 year of follow-up
Number of subjects: 549
Study: 38431300

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral shoulders (control)
Number of subjects: 30
Study: 38431445

Group type: EXPERIMENTAL
Intervention: Hemin (4 mg/kg)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 38431766

Group type: EXPERIMENTAL
Intervention: Systemic or topical interventions (specifics not provided)
Number of subjects: 16838

Group type: EXPERIMENTAL
Intervention: Aggravating factors (foods, seasonal changes, psychological factors)
Number of subjects: 16838

Group type: EXPERIMENTAL
Intervention: Comorbidities (chronic urticaria, food allergies, diabetes)
Number of subjects: 16838

Group type: EXPERIMENTAL
Intervention: Age of AD onset (≥60 years)
Number of subjects: 16838

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis and hypertension
Number of subjects: 16838
Study: 38431848

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal problems and social functioning
Number of subjects: 0
Study: 38432027

Group type: EXPERIMENTAL
Intervention: Patients aged 80 years and older
Number of subjects: 26193

Group type: COMPARATOR
Intervention: Patients under 80 years
Number of subjects: 26193

Group type: EXPERIMENTAL
Intervention: Older patients (≥80 years)
Number of subjects: 26193
Study: 38432233

Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (600 mg orally every 8 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (500 mg amoxicillin and 125 mg clavulanic acid orally every 8 h)
Number of subjects: 30
Study: 38432236

Group type: EXPERIMENTAL
Intervention: GP-targeted plus patient-targeted feedback
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: GP-targeted feedback
Number of subjects: 1030

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 1030
Study: 38432247

Group type: EXPERIMENTAL
Intervention: Cetuximab 500 mg/m2
Number of subjects: 82

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 82
Study: 38432471

Group type: EXPERIMENTAL
Intervention: Enhancing Social Functioning for older Veterans with PTSD (ESVP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support group control
Number of subjects: 0
Study: 38432562

Group type: EXPERIMENTAL
Intervention: Recent dietary intake of fiber
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Habitual dietary intake of fiber
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Habitual soluble fiber intake
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Recent legume intake
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Habitual legume intake
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Recent vegetable intake
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Habitual vegetable intake
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Recent Healthy Eating Index (HEI) scores
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index scores for recent intake
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Recent and habitual fiber, legume, vegetable, and fruit intake (excluding clinically elevated calprotectin)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Recent total HEI score
Number of subjects: 358
Study: 38432713

Group type: EXPERIMENTAL
Intervention: 1 cup of freeze-dried blueberry powder
Number of subjects: 115

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 115
Study: 38432714

Group type: EXPERIMENTAL
Intervention: Prenatal supplementation (daily oral multiple micronutrient supplementation including 50 μg/d of vitamin B-12)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Postnatal supplementation (postnatal supplement including 50 μg/d of vitamin B-12)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control (placebo) during prenatal or postnatal periods
Number of subjects: 412
Study: 38432715

Group type: EXPERIMENTAL
Intervention: AAIM tool for diagnosing malnutrition
Number of subjects: 290
Study: 38432810

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Foam Rolling Recovery (FRR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 37
Study: 38433074

Group type: EXPERIMENTAL
Intervention: Nurse-led supportive care program for 8 weeks (4 weeks face-to-face, 4 weeks via phone)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nurse-led supportive care program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 42
Study: 38433091

Group type: EXPERIMENTAL
Intervention: Omission of breast surgery after NST for patients predicted to have pCR based on MRI and VAB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous studies where patients with pCR underwent breast surgery
Number of subjects: 0
Study: 38433125

Group type: EXPERIMENTAL
Intervention: DEX1 (Dexamethasone on day 1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: DEX4 (Dexamethasone on days 1-4)
Number of subjects: 76
Study: 38433191

Group type: EXPERIMENTAL
Intervention: 5-FU (200 µg/ml) and LMWH (5 IU/ml)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study: 38433424

Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride
Number of subjects: 57
Study: 38433714

Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) models
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: RNA sequencing (RNA-seq) profiling
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing (single-cell RNA-seq)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PDX-derived organoids (PDXO) and patient-derived organoids (PDO)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Preclinical models
Number of subjects: 51
Study: 38433842

Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (5 micrograms, administered intramuscularly at day 84 and day 140)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (standard TB treatment only)
Number of subjects: 18
Study: 38433888

Group type: EXPERIMENTAL
Intervention: Durvalumab plus etoposide and platinum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide and platinum
Number of subjects: 0
Study: 38434590

Group type: EXPERIMENTAL
Intervention: Informal home mindfulness practice
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Formal home mindfulness practice
Number of subjects: 21
Study: 38434594

Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing
Number of subjects: 149

Group type: COMPARATOR
Intervention: Measure of Immigration and Acculturation Stressors (MIAS)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Measure of Drinking in Response to Immigration and Acculturation Stressors (MDRIAS)
Number of subjects: 149
Study: 38434639

Group type: EXPERIMENTAL
Intervention: Lactoferrin (Lf) in oral nutritional supplements (ONS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 38434698

Group type: EXPERIMENTAL
Intervention: α-Mangostin hydrogel film
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38434770

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 48
Study: 38435072

Group type: EXPERIMENTAL
Intervention: CKD-CDS intervention
Number of subjects: 6420

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6420
Study: 38435286

Group type: EXPERIMENTAL
Intervention: First-line brigatinib followed by lorlatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-line brigatinib followed by lorlatinib
Number of subjects: 0
Study: 38435429

Group type: EXPERIMENTAL
Intervention: Pharmacy Integrated Community Care (PICC) program - a structured, four-session group-based program guided by experienced pharmacists focusing on medication adherence and diabetes management.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard Diabetes Mellitus Adherence Clinic program (Control group).
Number of subjects: 94
Study: 38435809

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (sevoflurane-dexmedetomidine with continuous infusion of lidocaine and ketamine)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (sevoflurane-remifentanil with morphine transition)
Number of subjects: 172
Study: 38435944

Group type: EXPERIMENTAL
Intervention: Postoperative hyperamylasemia (POH) defined as serum amylase >100 U/L on postoperative day 1 (POD1)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Patients without postoperative hyperamylasemia (POH)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Postoperative hyperamylasemia (POH)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Blood loss >350 mL, pancreatic duct size <3 mm, elevated POD1 serum amylase >100 U/L
Number of subjects: 140
Study: 38435978

Group type: EXPERIMENTAL
Intervention: Web-based EMDR intervention (up to 12 sessions, delivered twice weekly)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Web-based EMDR intervention
Number of subjects: 42
Study: 38436050

Group type: EXPERIMENTAL
Intervention: Endothelial function (LnRHI)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (CIMT)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Vascular stiffness (cfPWV)
Number of subjects: 214
Study: 38436075

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 2635

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 2635

Group type: EXPERIMENTAL
Intervention: Torsemide and Furosemide
Number of subjects: 2635
Study: 38436174

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 75

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 75
Study: 38436365

Group type: EXPERIMENTAL
Intervention: One-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38436463

Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg once a day for 14 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delpazolid 400 mg twice a day for 14 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg twice a day for 14 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delpazolid 1200 mg once a day for 14 days
Number of subjects: 63
Study: 38436495

Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (2.7 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal naloxone (4 mg)
Number of subjects: 0
Study: 38436589

Group type: EXPERIMENTAL
Intervention: Blood samples analyzed for lactate dehydrogenase, immunoglobulin E, interleukins, thymus and activation-regulated chemokine, and lymphocyte subpopulations.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Digital spatial profiling and single-cell RNA sequencing of the lymphoma microenvironment.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Microbiological sampling and analysis of skin barrier function.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Evaluation of life quality parameters.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group of 20 healthy volunteers.
Number of subjects: 120
Study: 38436824

Group type: EXPERIMENTAL
Intervention: Dynamic whole-body PET acquisition protocol
Number of subjects: 8
Study: 38436921

Group type: EXPERIMENTAL
Intervention: DAAs (sofosbuvir/velpatasvir)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Postponed DAAs
Number of subjects: 84
Study: 38436924

Group type: EXPERIMENTAL
Intervention: Regular-strength dual-action tablets (RS-DAT) - niraparib 200 mg/AA 1000 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower-strength dual-action tablets (LS-DAT) - niraparib 100 mg/AA 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent combination (SAC) - abiraterone acetate alone
Number of subjects: 0
Study: 38436944

Group type: EXPERIMENTAL
Intervention: HOPE (digital therapist-guided prolonged exposure programme)
Number of subjects: 0
Study: 38436947

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) 38% concentration solution
Number of subjects: 7418

Group type: COMPARATOR
Intervention: Sealants with Atraumatic Restorative Treatment (ART)
Number of subjects: 7418